About Monogram Technologies Inc. - Common Stock (MGRM)
Monogram Technologies Inc. is a company focused on developing innovative solutions in the field of biotechnology and healthcare. It specializes in advancing personalized medicine through its proprietary technologies that aim to enhance patient care and treatment outcomes. By leveraging cutting-edge research and data analytics, Monogram Technologies works to unlock the potential of genomic insights, enabling healthcare providers to tailor therapies to individual patients. The company's mission is to transform the way diseases are diagnosed and treated, ultimately contributing to improved health and well-being for individuals worldwide. Read More
NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Monogram Technologies Inc. (NasdaqCM: MGRM) to Zimmer Biomet Holdings, Inc. (NYSE: ZBH). Under the terms of the proposed transaction, shareholders of Monogram will receive an upfront payment of $4.04 per share in cash, and a non-tradeable contingent value right entitling the holder to receive up to $12.37 per share of common stock in cash if certain product development, regulatory and revenue milestones are achieved through 2030. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
BALA CYNWYD, Pa., July 14, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Zimmer Biomet plans to acquire Monogram and integrate its robotic knee system into its ROSA platform to support growth and product expansion through 2027.
The Ademi Firm is investigating Monogram (NASDAQ: MGRM) for possible breaches of fiduciary duty and other violations of law in its transaction with Zimmer Biomet.
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Monogram Technologies Inc. (NASDAQ: MGRM) to Zimmer Biomet Holdings, Inc. is fair to Monogram shareholders. Under the terms of the proposed transaction, Monogram shareholders would receive an upfront payment of $4.04 per share in cash, and a non-tradeable contingent value right entitling the holder to receive up to $12.37 per share of common stock in cash if certain product development, regulatory and revenue milestones are achieved through 2030.
AUSTIN, TEXAS / ACCESS Newswire / July 8, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company revolutionizing orthopedic surgery, today announced the mandatory conversion of all outstanding shares of 8.00% Series D Convertible Cumulative Preferred Stock (the "Series D Preferred Stock") that were issued in connection with the Company's offering that closed on October 1, 2024 (the "Offering"). During the Offering, the Company issued and sold units, with each unit consisting of (a) one share of the Company's Series D Preferred Stock and (b) one common stock purchase warrant to purchase one share of the Company's common stock, $0.001 par value per share (the "Common Stock").
AUSTIN, TX / ACCESS Newswire / May 6, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company revolutionizing orthopedic surgery, will hold a conference call webcast on Wednesday, May 14, 2025 at 4:30 p.m. Eastern Time in conjunction with its reported financial results for the first quarter ended March 31, 2025, and to discuss regulatory updates, including its recent FDA 510(k) Clearance for the Monogram mBôsTM TKA System and approval to start clinical trials in India, and key milestones. A press release detailing these results will be issued prior to the call.
Monogram Technologies (NASDAQ: MGRM), an AI-driven robotics company transforming orthopedic surgery, has received approval from India’s Central Drugs Standard Control Organization to import its mBôs TKA system and begin a 102-patient, multi-center clinical trial in partnership with Shalby Limited (NSE: SHALBY). The study will evaluate the safety and effectiveness of Monogram’s robotic total knee replacement system using a Consensus CKS implant and include three-month clinical follow-up across multiple Indian sites. Monogram will deploy full-time staff to support training and execution, with surgeries expected to begin within 90 business days. CEO Benjamin Sexson called the approval a major milestone toward commercial launch, while partners from Reliance Life Sciences and Shalby praised the trial’s potential to elevate global orthopedic standards.
AUSTIN, TX / ACCESS Newswire / March 20, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, is pleased to announce its partnership with Urvin, a private, verified message board exclusively for active Monogram shareholders. This platform offers a way for shareholders to communicate directly with each other while providing Monogram with an additional tool to provide important company updates and reach the broadest possible shareholder audience.
